logo
Share SHARE
FONT-SIZE Plus   Neg

Novo Nordisk Says FDA Approves To Update Victoza Product Label

Novo Nordisk A/S (NVO) said Friday that the US Food and Drug Administration has approved to update the product label for Victoza to include data showing superior blood sugar control and weight reduction when compared to Januvia.
The update also includes data showing the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes.

The label update is based on data from two large, randomized, open-label studies in adults with type 2 diabetes.

"The data from these studies further demonstrate the strong clinical profile and the value of Victoza in the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations.
comments powered by Disqus
Follow RTT